

Treatment of non atypical and atypical endometrial hyperplasia with a levonorgestrel releasing intrauterine system

D. Wildemeersch*, M.D., M. Dhont**, M.D.

*Gynecological research unit, Knokke, Belgium

**Head, Dept. Obstetrics and Gynecology, University Hospital Ghent, Belgium

Condensation

The results suggest that the "frameless" 14 µg/d releasing FibroPlant-LNG system is an effective method to treat women with non atypical and typical hyperplasia.

Abstract

Objective: A "frameless" intrauterine drug delivery system releasing 14 µg/d of levonorgestrel (LNG) was used to treat non atypical and typical endometrial hyperplasia in 12 women.

Study design: Non-comparative study with up to 3 to 4 years follow-up.

Results: The cure rate was 100% as confirmed by repeat endometrial biopsy.

Conclusion: This method could be considered an alternative to hysterectomy.